Kangai injection treatment of lung cancer after chemotherapy related fatigue effect.docVIP

 PAGE \* MERGEFORMAT 8 Kangai injection treatment of lung cancer after chemotherapy related fatigue effect Of: Jing Cheng Lin Wang Jun Jiang Zhenyu years [Keywords:] lung cancer; chemotherapy; cancer related fatigue; Kangai injection Cancer related fatigue (CRF) is the most common symptoms of cancer patients, one is caused by the cancer or cancer treatment as a continuous subjective fatigue (1), seriously affecting the quality of life of patients. In recent years with quality of life of cancer patients on continuous progress, CRF to more attention. I Since 2007, application Kangai injection treatment of lung cancer after chemotherapy in patients with CRF to good effect. 1 Materials and Methods 1.1 Clinical data are not suitable for 87 patients surgery b ~ non-small cell lung cancer (NSCLC) patients were confirmed by cytology or pathology, physical condition score (Karuafsky)gt; 60 points; expected lifetime ofgt; 3 months; good compliance of patients to obtain informed consent. According to hospital patients were divided into two group numbers, odd for the treatment group, even for the control group, treatment group, 44 patients, 24 male and 20 female; 24 patients with adenocarcinoma of , 20 cases of squamous cell carcinoma; clinical stage b of the 27 cases, stage 17; age 46 to 70 years, mean 60.5 years old. the control group of 43 patients, 23 males and 20 females; 22 cases of adenocarcinoma, squamous cell carcinoma 21 cases; clinical stage b of 25 cases, of 18 cases; aged 45 to 70 years, mean 61.3 years; the two groups in gender, age, tumor histological type, clinical stage, and so the difference was not statistically significant ( Pgt; 0.05). 1.2 Treatment of lung cancer patients in both groups are used (NP) program (vinorelbine 25 mg/m2, on days 1,8, intravenous infusion; cisplatin 75 mg/m2, points 1 to 3 or 4 days iv drip); lung carcinoma patients were treated (DP) program (Docetaxel 60 mg/m2, points on days 1,8, iv; cisplatin 75 mg/